Lanean...
Targeted Opioid Receptor Antagonists in the Treatment of Alcohol Use Disorders
In 1994, the US Food and Drug Administration approved the μ-opioid receptor antagonist naltrexone to treat alcohol dependence. However, treatments requiring daily administration, such as naltrexone, are inconsistently adhered to in substance abusing populations, and constant medication exposure can...
Gorde:
| Argitaratua izan da: | CNS Drugs |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2013
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4600601/ https://ncbi.nlm.nih.gov/pubmed/23881605 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-013-0096-4 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|